The Global Progressive Multifocal Leukoencephalopathy (PML) Treatment Industry is on the brink of a transformative journey, as recent research projects a surge in market value from US$ 1,320 million in 2023 to an anticipated US$ 1,773.97 million by 2033, exhibiting a commendable Compound Annual Growth Rate (CAGR) of 3% from 2023 to 2033.
The market’s growth trajectory has been noteworthy, with a 2% CAGR observed from 2018 to 2022. This remarkable expansion signifies a burgeoning demand for Progressive Multifocal Leukoencephalopathy treatments, reflecting the industry’s commitment to addressing the pressing healthcare needs of patients.
North America is expected to gain a market share of around 40% throughout the projection period. This increase is due to the increasing incidence of the illness in the region. Furthermore, government efforts and an increase in the number of research collaborations are encouraging market expansion in North America. Because of a shift towards point-of-care healthcare, Asia Pacific is a booming market. The growing number of hospitals in India and China creates a global business opportunity.
Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-16711
Key Takeaways from the Global Progressive Multifocal Leukoencephalopathy Treatment Industry Study
- The Progressive Multifocal Leukoencephalopathy Treatment market increased at a 2% CAGR from 2018 to 2022.
- From 2023 to 2033, the global Progressive Multifocal Leukoencephalopathy Treatment market is estimated to rise at a 3% CAGR.
- The Progressive Multifocal Leukoencephalopathy Treatment Market is anticipated to be worth US$ 1773.97 million by 2033.
- Hospital pharmacies have the biggest market share, according to the FMI research.
- North America is estimated to have 40% of the market for Progressive Multifocal Leukoencephalopathy Treatment.
- The South and East Asia market is expected to grow significantly throughout the projected period, accounting for 20% of the total.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Progressive Multifocal Leukoencephalopathy Treatment.” says an FMI analyst
Ask Us Your Questions About This Report https://www.futuremarketinsights.com/ask-question/rep-gb-16711
Global Progressive Multifocal Leukoencephalopathy Treatment Industry Competition
Key players in the market include pharmaceutical companies such as NeoImmuneTech, Neurimmune, GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc., Novartis AG, AbbVie Inc., and Bristol-Myers Squibb Company along with healthcare providers and technology companies among other global players.
- In October 2022, Cellevolve Bio, Inc., a company focused on developing and commercializing cell therapies, announced that its Investigational New Drug (IND) application for CE-VST01-JC has been approved by the US Food and Drug Administration (FDA). CE-VST01-JC is a JC Virus Specific T Cell Therapy that is being studied for the treatment of progressive multifocal leukoencephalopathy (PML) and has received orphan drug designation from the FDA.
- The safety and effectiveness of CE-VST01-JC will be tested in a global, multi-center, randomized, double-blind, placebo-controlled Phase 2 study called ASCEND-JC. The study is expected to enroll up to 60 patients across the US, Canada, and EU, with the first patient enrollment anticipated in the first half of 2023.
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Progressive Multifocal Leukoencephalopathy Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights based on indication, treatment, distribution channel, end-users and region.
Click Here To Buy Your Full Report https://www.futuremarketinsights.com/checkout/16711
Key Segments Profiled in the Global Progressive Multifocal Leukoencephalopathy Treatment Industry Survey
Treatment:
- Anti-retroviral Therapy
- Antiviral/Anti JCV
- Other Symptomatic
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Indication:
- HIV/AIDS
- Organ Transplantation
- Multiple Sclerosis
- Hematologic Malignancies
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
